Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, Alexandra; Makarov, Vladimir; Merghoub, Taha; Yuan, Jianda; M. Zaretsky, Jesse; Desrichard, Alexis; A. Walsh, Logan; A. Postow, Michael; Wong, Phillip; Ho, Teresa; J. Hollmann, Travis; Bruggeman, Cameron; Kannan, Kasthuri; Li, Yanyun; Elipenahli, Ceyhan; Liu, Cailian; Harbison, Christopher; Wang, Lisu; Ribas, Antoni; D. Wolchok, Jedd; A. Chan, Timothy

doi:10.1056/nejmoa1406498

Public

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Published in New England Journal of Medicine • Nov 20, 2014

Authors:

Alexandra Snyder

Vladimir Makarov

Taha Merghoub

Abstract

BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanom...

Subject

Ipilimumab

Tremelimumab

CTLA-4

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!